Takeda Business Division’s Masato Iwasaki: We Will Not Join Promotion Of SGLT-2 Inhibitors
This article was originally published in PharmAsia News
Executive Summary
Takeda does not plan to join in the promotional activities of SGLT-2 inhibitors despite the expected approval of its own oral hypoglycemic SGLT-2 inhibitor in 2014, the company’s Business Division Head Masato Iwasaki said Nov. 20.